A Study of LY317615 in Patients With Brain Tumors

Phase 2CompletedNCT00190723

Eli Lilly and Company120 enrolled

Overview

1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Malignant Glioma

Interventions

EnzastaurinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * You must be at least 18 years old * You must have been diagnosed with a recurrent brain tumor by MRI or CT scan * You must be able to swallow the LY317615 tablets Exclusion Criteria: * You are a woman who is pregnant or breastfeeding * In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Bethesda, Maryland, United States

Outcomes

Primary Outcomes

To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.

Secondary Outcomes

To obtain preliminary information regarding the spectrum of toxicities of LY317615 administered to patients with recurrent high-grade gliomas

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.